

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/047291 A2

(51) International Patent Classification:
C07K 16/00 (2006.01)

(21) International Application Number:
PCT/US2006/039682

(22) International Filing Date: 11 October 2006 (11.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/251,561 14 October 2005 (14.10.2005) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 11/251,561 (CON)
Filed on 14 October 2005 (14.10.2005)

(71) Applicants (for all designated States except US):
CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP];
5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543 (JP).
XENCOR, INC. [US/US]; 111 West Lemon Avenue,
Monrovia, California 91016 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAZAR, Gregory Alan** [US/US]; 3100 Riverside Drive #139, Los Angeles, California 90027 (US). **DAHIYAT, Bassil I.** [US/US]; 3829 Luna Court, Altadena, California 91001 (US). **OKABE, Hisafumi** [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 200, Kajiwara, Kamakura-shi, Kanagawa 247-8530 (JP). **SUGIMOTO, Masamichi** [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 200, Kajiwara, Kamakura-shi, Kanagawa 247-8530 (JP). **IJIMA, Shigeyuki**

[JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 135, Komakado 1-chome, Gotemba-shi, Shizuoka 412-8513 (JP). **SUGO, Izumi** [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 135, Komakado 1-chome, Gotemba-shi, Shizuoka 412-8513 (JP).

(74) Agent: **FRASER, Janis K., Ph.D., J.D.**; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-GLYPICAN-3 ANTIBODY



(57) Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.

ANTI-GLYPICAN-3 ANTIBODY

TECHNICAL FIELD

The present invention relates to an anti-glypican-3 antibody. Specifically, the present invention relates to an anti-glypican-3 antibody which has modifications in the amino acid sequence of the Fc region and exhibits enhanced ADCC activity.

BACKGROUND

Glypican-3 (GPC3) is one of a heparan sulfate proteoglycan family existing on the surface of cells, and it is suggested that GPC3 may participate in cell division in development and in growth of cancer cells, but its function is not as yet well clarified.

It has been found that a certain antibody binding to GPC3 has a cell growth-inhibiting effect through its ADCC (antibody-dependent cytotoxicity) activity and CDC (complement-dependent cytotoxicity) (WO2003/000883, hereby incorporated by reference in its entirety).

In the case where an anticancer agent utilizing the cytotoxicity activity of an antibody is developed, it is desirable that the antibody to be used has enhanced ADCC activity. Thus, an anti-GPC3 antibody having enhanced cytotoxicity activity is desired for the GPC3-recognizing antibody.

An object of the invention is to provide an anti-GPC3 antibody having enhanced cytotoxicity as compared with conventional antibodies.

SUMMARY

It was found that an anti-glypican-3 antibody with enhanced ADCC activity may be obtained by modifying the amino acid sequence in the Fc region of the antibody.

In one aspect, the present invention provides an anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region.

In another aspect, the present invention provides an anti-glypican-3 antibody in which one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues.

In another aspect, the present invention provides an anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with another amino acid residue;
- (b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with other amino acid residues;
- (c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with other amino acid residues;
- (d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with other amino acid residues;
- (e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with other amino acid residues.

In another aspect, the present invention provides an anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody having glutamic acid at the position 332 of the Fc region;
- (b) an anti-glypican-3 antibody having aspartic acid at the position 239, leucine at the position 330, and glutamic acid at the position 332 of the Fc region;
- (c) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, and glutamic acid at the position 332 of the Fc region;
- (d) an anti-glypican-3 antibody having aspartic acid at the position 239, threonine at the position 326, and glutamic acid at the position 332 of the Fc region;
- (e) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, glutamic acid at the position 326, and glutamic acid at the position 332 of the Fc region.

In another aspect, the present invention provides an anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with glutamic acid;

(b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with aspartic acid, leucine, and glutamic acid, respectively;

(c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with aspartic acid, alanine, and glutamic acid, respectively;

(d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with aspartic acid, threonine, and glutamic acid, respectively;

(e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with aspartic acid, alanine, glutamic acid, and glutamic acid, respectively.

In another aspect, the present invention provides an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.

In another aspect, the present invention provides a method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

(i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody in which one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 of the Fc region are substituted by other amino acid residues; and

(ii) isolating the antibody from the culture.

In another aspect, the present invention provides a method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

(i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody selected from the group consisting of:

(a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with another amino acid residue;

(b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with other amino acid residues;

(c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with other amino acid residues;

(d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with other amino acid residues;

(e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with other amino acid residues; and

(ii) isolating the antibody from the culture.

In another aspect, the present invention provides a method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

(i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody selected from the group consisting of:

(a) an anti-glypican-3 antibody having glutamic acid at the position 332 of the Fc region;

(b) an anti-glypican-3 antibody having aspartic acid at the position 239, leucine at the position 330, and glutamic acid at the position 332 of the Fc region;

(c) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, and glutamic acid at the position 332 of the Fc region;

(d) an anti-glypican-3 antibody having aspartic acid at the position 239, threonine at the position 326, and glutamic acid at the position 332 of the Fc region;

(e) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, glutamic acid at the position 326, and glutamic acid at the position 332 of the Fc region; and

(ii) isolating the antibody from the culture.

In still another aspect, the present invention provides an anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 34;
- (b) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 35;
- (c) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 36;
- (d) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 37; and
- (e) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 38.

DESCRIPTION OF DRAWINGS

Fig. 1 shows the scheme for preparing the Fc-modified humanized anti-glypican-3 antibody of the invention.

Fig. 2 shows the result of SDS-PAGE analysis of a purified Fc-modified humanized anti-glypican-3 antibody of the invention.

Fig. 3 shows a chromatogram of a purified Fc-modified humanized anti-glypican-3 antibody analyzed through a gel permeation column.

Fig. 4 shows the ADCC activity against SK-03 cells of the Fc-modified and wild-type humanized anti-glypican-3 antibodies, using human peripheral blood-derived PBMC.

Fig. 5 shows the ADCC activity against HepG2 cells of the Fc-modified and wild-type humanized anti-glypican-3 antibodies, using mouse marrow-derived effector cells.

DETAILED DESCRIPTION

The present invention provides an antibody having modifications in the Fc region. Fig. 1 shows the structure and preparation scheme of the Fc-modified humanized anti-glypican-3 antibody of the invention.

In general, the antibody is a heterotetramer of about 150,000 daltons, and comprises two same light (L) chains and two same heavy (H) chains. Each light chain is bound to the heavy chain via one covalent disulfide bond, and the number of the disulfide

bonds between the heavy chains varies depending on the isotype of antibody. The heavy chain and the light chain each have intra-chain disulfide bridges at certain intervals. Each heavy chain has a variable domain (VH) at one terminal thereof, and has many constant domains linked thereto. Each light chain has a variable domain (VL) at one terminal thereof and has a constant region at the other terminal thereof. The constant region of the light chain is in parallel to the first constant region of the heavy chain, and the variable region of the light chain is in parallel to the variable region of the heavy chain. It is believed that specific amino acid residues form an interface of the variable domain of the light chain and the heavy chain (Clothia et al., J. Mol. Biol., 186:651-666 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. USA 82:4592-4596 (1985), all hereby incorporated by reference in its entirety).

The light chain of a vertebrate-derived antibody may be classified into two different types, referred to as kappa (κ) and lambda (λ), based on the amino acid sequence of the constant region thereof. In addition, the antibody may be classified into different classes based on the amino acid sequence of the constant domain of the heavy chain thereof. The antibody includes at least five main classes: IgA, IgD, IgE, IgG and IgM, and some of them may be classified into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3 and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains of different classes are referred to as α , δ , ϵ , γ and μ . The subunit structure and the three-dimensional structure of immunoglobulin of each class are known in the art. It is also known that there exist allotypes in the sequence of the Fc region of IgG-1, for example, G1m(1), nG1m(1), G1m(2), G1m(3), nG1m(17), etc. (M. S. Schanfield and E. van Loghem, "Human Immunoglobulin Allotypes" Handbook of Experimental Immunology, Vol.3, ch94, pp1-18, Blackwell Scientific Publishers. Oxford, U.K. 1986, 4th Edition, hereby incorporated by reference in its entirety).

Fc region means a region of an Fc fragment of an antibody molecule, comprising a part of hinge, CH2 and CH3 domains and having a molecular weight of about 50,000. A human IgG heavy chain Fc region is from the 225th threonine to the C-terminal, in the case that the molecule is digested with papain (Burton, D. R. 1985. Immunoglobulin G: functional sites. Mol. Immunol. 22:161-206, hereby incorporated by reference in its entirety).

The numbering of the amino acid position as used herein refers to the method of "EU index" by Kabat et al (Kabat EA et al., 1991, Sequence of Proteins of Immunological Interest. 5th Ed. NIH, hereby incorporated by reference in its entirety).

The Fc region binds to an Fc receptor (FcR) present on the cell surface of effector cells, such as macrophages and NK cells. The Fc receptor participates in antibody-dependent cytotoxicity (ADCC), anaphylaxis reaction, id reaction, etc. The type of Fc receptor varies, depending on the subtype of immunoglobulin. For example, Fc receptor of IgG is Fc γ receptor; Fc receptor of IgE is Fc ϵ receptor; and Fc receptor of IgA is Fc α receptor.

The CH2-CH3 domain consists of the CH2 domain and the CH3 domain. The CH2-CH3 domain of a human IgG heavy chain is from the 233th alanine to the C-terminal.

Fc-modified antibody

The antibody of the invention is an Fc-modified antibody in which the amino acid sequence in the Fc region is modified. "Modification" or "site-specific mutagenesis (mutagenesis)" used in the invention includes substituting an original (unmodified) amino acid residue with any other amino acid residue, deletion of an original amino acid residue, and addition of an additional amino acid residue, but preferably indicates substitution of an original amino acid residue with any other amino acid residue. The original (unmodified) amino acid sequence as referred to herein is usually a natural Fc region sequence. In this context, "modification" and "mutagenesis" of amino acid residue are used in the same meaning.

In the invention, modification of amino acid residues may be effected by mutating the DNA that codes for the antibody.

In the invention, "mutation of DNA" means that DNA is mutated in such a manner that it may correspond to the amino acid residue to be modified. More specifically, it means that the DNA coding for the original amino acid residue is mutated to DNA coding for the amino acid residue to be modified. In general, it means genetic engineering or mutagenesis treatment for insertion, deletion or substitution of at least one nucleotide of the original DNA so as to give a codon that codes for the intended amino

acid residue. Specifically, the codon that codes for the original amino acid residue is substituted with the codon that codes for the amino acid residue to be modified. Those skilled in the art may easily carry out such a DNA mutation according to a known technique, for example, according to a site-specific mutagenesis method such as PCR mutagenesis method (Hashimoto-Gogoh, T. et al., (1995) *Gene* 152, 271-275; Zoller, MJ, and Smith, M., (1983) *Methods Enzymol.*, 100, 468-500; Kramer, W. et al., (1984) *Nucleic Acids, Res.*, 12, 9441-9456; Kramer W. and Fritz HJ, (1987) *Methods Enzymol.*, 154, 350-367; Kunkel, TA, (1985) *Proc. Natl. Acad. Sci. USA*, 82, 488-492; Kunkel, (1988) *Methods Enzymol.*, 85, 2763-2766, all hereby incorporated by reference in its entirety).

The number of the amino acid residues in the Fc region to be modified in the invention is not specifically limited, but one or more (for example, from 1 to 30, or 2, 3, 4 or 5) amino acid residues may be modified.

Preferably, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. In addition, any amino acid residues of the Fc region may be substituted with those of any allotypes of IgG1, for example, with the amino acid residues of G1m(1) and nG1m(1).

The anti-glypican-3 antibody of the invention is not specifically limited so far as it binds to glypican-3, but preferably, the antibody specifically binds to glypican-3. The gene sequence and the amino acid sequence of glypican-3 are known (Lage, H. et al., *Gene* 188 (1997), 151-156, hereby incorporated by reference in its entirety). The anti-glypican-3 antibody of the invention is preferably IgG, more preferably IgG1.

Cytotoxicity

The anti-glypican-3 antibody of the invention containing modified Fc region exhibits enhanced cytotoxicity activity as compared with the anti-glypican-3 antibody having a natural or wild type Fc region.

Cytotoxicity activity includes, for example, antibody-dependent cell-mediated cytotoxicity (ADCC) activity, and complement-dependent cytotoxicity (CDC) activity. In the invention, the CDC activity means a cytotoxicity activity caused by a complement system; and the ADCC activity means that, when a specific antibody adheres to the cell

surface antigen of a target cell, then an Fc γ receptor-having cell (e.g., immunocyte) binds to the Fc region via an Fc γ receptor to thereby impair the target cell.

Determination of whether an antibody has ADCC activity or CDC activity may be carried out according to a known method (for example, see Current Protocols in Immunology, Chapter 7, Immunologic Studies in Humans, Editor, John E. Coligan et al., John Wiley & Sons, Inc. (1993), hereby incorporated by reference in its entirety).

For example, the ADCC activity may be determined by mixing an effector cell, a target cell and an anti-glypican-3 antibody, then analyzing it for the degree of ADCC activity. The effector cell may include, for example, a mouse spleen cell, or a monocyte isolated from marrow or human peripheral blood. The target cell may include an established human cell line such as human hepatocyte cell line HuH-7. An anti-glypican-3 antibody is added to the target cell previously labeled with ^{51}Cr and incubated, then an effector cell is added in a suitable ratio to the target cell. After incubation, the supernatant is collected and analyzed for radioactivity to determine the ADCC activity of the antibody.

The CDC activity may be determined by mixing the above-mentioned labeled target cell and an anti-glypican-3 antibody, adding a complement to the mixture and incubating, and then analyzing the supernatant for radioactivity.

Antibody

The term "antibody" as referred to herein is used in the broadest sense of the word, indicating any and every antibody that includes monoclonal antibody (including full-length monoclonal antibody), polyclonal antibody, antibody mutant, antibody fragment, poly-specific antibody (e.g., bispecific antibody), chimera antibody, humanized antibody and others, so far as it shows the desired biological activity.

Antibody and immunoglobulin are proteins having the same structure characteristics, and the antibody in the invention includes immunoglobulin.

The term "monoclonal antibody" as referred to herein indicates an antibody obtained from a group of substantially homogeneous antibodies, or that is, an antibody group in which all individual antibodies are uniform except minor mutants that may occur in nature. A monoclonal antibody is highly specific and generally acts on a single

antigen site. Further, as compared with conventional polyclonal antibody preparations that typically include different antibodies to different epitopes, each monoclonal antibody is directed to a single epitope on an antigen. In addition to the specificity thereof, a monoclonal antibody has another advantage in that it is synthesized through culture of a hybridoma which is not contaminated with any other antibodies. The modifier "monoclonal" suggests the nature of the antibody obtained from a group of substantially uniform antibodies, and it does not require that the antibody be produced by a specific method. For example, the monoclonal antibody for use in the invention may be produced, for example, according to a hybridoma method (Kohler and Milstein, *Nature* 256:495 (1975), hereby incorporated by reference in its entirety), or a recombination method (USP 4,816,567, hereby incorporated by reference in its entirety). The monoclonal antibody for use in the invention may also be isolated from a phage antibody library (Clackson et al., *Nature* 352:624-628 (1991); Marks et al., *J. Mol. Biol.*, 222:581-597 (1991), all hereby incorporated by reference in its entirety).

The term "antibody fragment" indicates a portion of a full-length antibody. The antibody fragment for use in the invention is preferably an antibody fragment that maintains an antibody-binding activity and maintains a cytotoxicity activity of the full-length antibody.

A multi-specific antibody is an antibody having specificity to at least two different antigens. In general, this type of molecule may bind to two antigens (that is, bispecific antibody), but in this description, the "multi-specific antibody" includes antibodies having specificity to more than two (for example, three) antigens. The multi-specific antibody may be a full-length antibody or a fragment of such an antibody. For example, the bispecific antibody may recognize two different antigens or may recognize different epitopes of one antigen. In addition, one may recognize a cytotoxic substance.

The antibody of the present invention may also be a chimera antibody or a humanized antibody. In general, a chimera antibody comprises a variable region derived from an antibody of a non-human mammal, and a constant region derived from a human antibody. On the other hand, humanized antibody comprises a complementarity-determining region derived from a non-human mammal, and a framework region and a constant region derived from a human antibody.

The origin of the variable region in a chimera antibody, and the origin of a CDR in a humanized antibody are not specifically limited, but may be derived from any animals. For example, any sequences derived from mouse antibody, rat antibody, rabbit antibody, or camel antibody may be used (Cook WJ et al., Protein Eng. 1996 Jul 9(7):623-8; Tsurushita N et al., J Immunol Methods. 2004 Dec 295(1-2):9-19; Sato K et al, Mol Immunol. 1994 Apr 31(5):371-81; Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum Antibodies Hybridomas. 1992 Jul 3(3):137-45; Genetically engineered antibodies: progress and prospects. Crit Rev Immunol. 1992;12(3-4):125-68, all hereby incorporated by reference in its entirety).

For the constant region of a chimera antibody and a humanized antibody, those derived from a human antibody may be used. For example, C γ 1, C γ 2, C γ 3, C γ 4 may be used for the H-chain, and C κ and C λ may be used for the L-chain.

Chimera antibody is an antibody constructed by combining sequences derived from different animals, and for example, it is an antibody comprising the heavy chain and light chain variable regions of a mouse antibody and the heavy chain and light chain constant regions of a human antibody. Such a chimera antibody may be constructed in any known methods. For example, a DNA coding for a mouse antibody variable region and a DNA coding for a human antibody constant region are ligated, then inserted into an expression vector, and introduced into a host to produce the intended antibody.

A humanized antibody, also referred to as a reshaped human antibody, is constructed by transplanting a complementarity-determining region (CDR) of an antibody of a mammal except human, for example, a mouse antibody into the complementarity-determining region of a human antibody. A general genetic recombination method for making a humanized antibody is known in the art (see EP 125023; WO96/02576, hereby incorporated by reference in its entirety).

Specifically, a DNA sequence designed so as to ligate CDR of a mouse antibody with the framework region (FR) of a human antibody may be synthesized through PCR using, as a primer, several oligonucleotides constructed so as to have portions overlapping with the terminal region of both CDR and FR (see the method described in WO98/13388, hereby incorporated by reference in its entirety).

The framework region of a human antibody to be ligated with CDR is so selected that the complementarity-determining region may form a good antigen-binding site. If desired, the amino acids in the framework region of the variable region of the antibody may be substituted in order that the complementarity-determining region of the reshaped human antibody may form a suitable antigen-binding site (Sato, K. et al., *Cancer Res.* (1993) 53, 851-856, hereby incorporated by reference in its entirety).

In addition, those antibodies are also included in the antibody of the invention which have mutation in one or more amino acids in regions other than the specified sites in the Fc region mentioned above or CDR region, and which is functionally equivalent to the antibody of the invention.

For preparing a polypeptide that comprises a different amino acid sequence but is functionally equivalent to a certain polypeptide, a method of introducing a mutation into the polypeptide is well known to those skilled in the art. For example, those skilled in the art may introduce a mutation to the antibody of the invention according to a site-specific mutagenesis or the like to thereby prepare an antibody functionally equivalent to that antibody. Amino acid mutation may also occur spontaneously.

Preferably, an amino acid residue is mutated to another amino acid residue which has side chain properties close to that of the original one. For example, regarding the properties thereof, amino acid side chains include hydrophobic amino acids (A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T), aliphatic side chain-having amino acids (G, A, V, L, I, P), hydroxyl group-containing side chain-having amino acids (S, T, Y), sulfur atom-containing side chain-having amino acids (C, M), carboxylic acid and amido-containing side chain-having amino acids (D, N, E, Q), base-containing side chain-having amino acids (R, K, H), aromatic side chain-having amino acids (H, F, Y, W) (the parenthesized alphabets are the one-letter code for amino acids). It is known that a polypeptide having an amino acid sequence modified from the original amino acid sequence through deletion, addition and/or substitution with any other amino acid of one or more amino acid residues therein still substantially maintain the biological activity of the original polypeptide (Mark, D. F. et al., *Proc. Natl. Acad. Sci. USA* (1984) 81, 5662-5666; Zoller, M. J. & Smith, M., *Nucleic Acids Research* (1982) 10, 6487-6500; Wang, A. et al., *Science* 224, 1431-1433; Dalbadie-McFarland, G., et al., *Proc.*

Natl. Acad. Sci. USA (1982) 79, 6409-6413, all hereby incorporated by reference in its entirety).

The antibody for use in the invention may be a conjugated antibody bound with a various types of molecules, such as non-peptidic polymers such as polyethylene glycol (PEG), radioactive substances and toxins. Such a conjugated antibody may be obtained through chemical modification of the antibody. The method of chemical modification has been established in the art. The antibody of the invention may include these conjugated antibodies (D.J.King., Applications and Engineering of Monoclonal antibodies., 1998 T.J. International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol 93:8681, all hereby incorporated by reference in its entirety).

Antibody preparation

The antibody of the invention may be produced according to a method known to those skilled in the art. Specifically, DNA coding for the intended antibody is inserted into an expression vector. In this step, DNA is inserted into an expression vector in such a manner that it could be expressed under control of an expression control region, for example, an enhancer and a promoter. Next, a host cell is transformed with the expression vector and the antibody is expressed in the host cell. In this process, a combination of a suitable host and a suitable expression vector may be used.

Examples of the vector include M13 vector, pUC vector, pBR322, pBluescript, pCR-Script. For subcloning and separation of cDNA, for example, pGEM-T, pDIRECT and pT7 may also be used.

Expression vectors are especially useful for the purpose of antibody production. When E. coli such as JM109, DH5 α , HB101 or XL1-Blue is used as a host, the expression vector must indispensably have a promoter that drives efficient expression of the vector in E. coli, for example, lacZ promoter (Ward et al., Nature (1989) 341, 544-546; FASEB J. (1992) 6, 2422-2427, hereby incorporated by reference in its entirety), araB promoter (Better et al., Science (1988) 240, 1041-1043, hereby incorporated by reference in its entirety) or T7 promoter. The vector of this type also includes pGEX-5X-

1 (Pharmacia), QIA express system (QIAGEN), pEGFP, and pET (in this case, the host is preferably a T7 RNA polymerase-expressing BL21).

The vector may include a signal sequence for polypeptide secretion. For the signal sequence for polypeptide secretion, for example, pelB signal sequence (Lei, S. P. et al., Bacteriol. (1987) 169, 4397, hereby incorporated by reference in its entirety) may be used for production in periplasm of *E. coli*. The introduction of the vector into a host cell may be effected, for example, according to a calcium chloride method or an electroporation method.

In addition to the *E. coli* expression vectors, the vector used for polypeptide production in the invention includes, for example, mammal-derived expression vectors (e.g., pcDNA3 (Invitrogen), pEGF-BOS (Nucleic acids, Res., 1990, 18(17), p. 5322, hereby incorporated by reference in its entirety), pEF, pCDM8); insect cell-derived expression vectors (e.g., Bac-toBAC baculovirus expression system (GIBCO BRL), pBacPAK8); vegetable-derived expression vectors (e.g., pMH1, pMH2); animal virus-derived expression vectors (e.g., pHSV, pMV, pAdexLcw), retrovirus-derived expression vectors (e.g., pZIPneo), yeast-derived expression vectors (e.g., Pichia Expression Kit (Invitrogen), pNV11, SP-Q01), *Bacillus subtilis*-derived expression vectors (e.g., pPL608, pKTH50).

For expression in animal cells such as CHO cells, COS cells or NIH3T3 cells, the vector must indispensably have a promoter necessary for intracellular expression, for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108, hereby incorporated by reference in its entirety), MMTV-LTR promoter, EF1 α promoter (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322, hereby incorporated by reference in its entirety), CAG promoter (Gene (1991) 108, 193, hereby incorporated by reference in its entirety), CMV promoter. Preferably, the vector has a gene for screening of the transformed cells (e.g., drug-resistant gene capable of being differentiated by drug (e.g., neomycin, G418)). The vector having such characteristics includes, for example, pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, pOP13.

Further, for the purpose of stable gene expression and an increase in the number of gene copies in cells, a vector having a complementary DHFR gene (e.g., pCHOI) is introduced into CHO cells deficient in the nucleic acid synthetic pathway to complement

the deficiency and is amplified with methotrexate (MTX). For the purpose of transient expression of the gene, COS cells having an SV40T antigen-expressing gene on the chromosome is transformed with a vector having SV40 replication origin (e.g., pcD). The replication origin may also be derived from polyoma virus, adeno virus, bovine polyoma virus (BPV), etc. Further, for increasing the number of gene copies in a host cell system, the expression vector may contain a selected marker, such as aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyl transferase (Ecogpt) gene, dihydrofolate reductase (dhfr) gene.

Pharmaceutical composition

The invention also relates to a pharmaceutical composition containing the antibody of the invention. Since the antibody of the invention exhibits enhanced cytotoxicity activity, it is suitable for use in pharmaceutical compositions, and in particular, it is useful as an anticancer agent. Since it has been shown that an anti-glypican-3 antibody has a cytotoxicity against a hepatoma-derived cell line (e.g. WO03/00883, hereby incorporated by reference in its entirety), the antibody of the invention is particularly useful as a drug for treating hepatic cancer. When the antibody of the invention is used in pharmaceutical compositions, it is preferably a humanized antibody in view of the antigenicity to humans.

The pharmaceutical composition of the invention may contain a pharmaceutically-acceptable carrier. The pharmaceutically-acceptable carrier includes, for example, sterile water, physiological saline, stabilizer, excipient, antioxidant (e.g., ascorbic acid), buffer (e.g., phosphoric acid, citric acid, other organic acids), preservative, surfactant (e.g., PEG, Tween), chelating agent (e.g., EDTA), or binder. In addition, the pharmaceutical composition of the invention may further contain any other low-molecular polypeptides; proteins such as serum albumin, gelatin, or immunoglobulin; amino acids such as glycine, glutamine, asparagine, arginine, lysine; saccharides such as polysaccharides, monosaccharides; carbohydrates; sugar alcohols such as mannitol, sorbitol. When the composition is prepared as an aqueous solution for injection, it may be combined with an isotonic solution containing, for example, physiological saline, glucose or any other auxiliary agent, such as D-sorbitol, D-mannose, D-mannitol, sodium

chloride, and with a suitable dissolution aid such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, PEG), nonionic surfactant (e.g., Polysorbate 80, HCO-50).

If desired, the composition may be encapsulated into microcapsules (microcapsules of hydroxymethyl cellulose, gelatin, poly(methyl methacrylate), etc.), or may be formed into colloid drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, nanocapsules) (see Remington's Pharmaceutical Science, 16th edition, Oslo Ed., 1980, hereby incorporated by reference in its entirety). Further, a method of formulating slow-release drugs is known and may be applicable to the invention (Langer et al., J. Biomed. Mater. Res., 1981, 15:167-277; Langer, Chem. Tech., 1982, 12:98-105; USP 3,773,919; EP 58,481; Sidman et al., Biopolymers 1983, 22:547-556; EP 133,988).

The composition may be administered to patients either orally or parenterally, but preferably parenterally. The shape (preparation form) of the pharmaceutical composition of the invention is not specifically limited but includes, for example, injections, transnasal preparations, transpulmonary preparations, percutaneous preparations, freeze-dried preparations, solutions. Preferred are freeze-dried preparations.

Freeze-drying may be effected in any method well known to those skilled in the art (Pharm. Biotechnol., 2002, 13, 109-133; Int. J. Pharm., 2000, 203(1-2), 1-60; Pharm. Res., 1997, 14(8), 969-975, all hereby incorporated by reference in its entirety). For example, a solution of the composition is suitably aliquoted into freeze-drying vials or the like vessels, and put in a freezer or a freeze-dryer, or dipped in a coolant such as acetone/dry ice and liquid nitrogen. When the antibody preparation is formed into a high-concentration solution preparation, it may be prepared according to a method well known to those skilled in the art. For example, a membrane concentration method using a TFF membrane may be employed as described in J. Pharm. Sci., 2004, 93(6), 1390-1402, hereby incorporated by reference in its entirety.

The formulation for injection may be systemically or topically administered in a mode of, for example, intravenous injection, intramuscular injection, intraperitoneal injection or subcutaneous injection. Depending on the age and the condition of the patient to which the composition is administered, the administration method for it may be suitably selected. The dose may be selected, for example, from a range of from 0.0001

mg/kg of body weight to 1000 mg/kg of body weight for a unit dose. Alternatively, the dose may be selected from a range of from 0.001 to 100000 mg/body. However, the invention should not be limited to the dose and the administration method as above.

The invention is described in more detail with reference to the following Examples, to which, however, the invention should not be limited.

EXAMPLES

Example 1: Production of Fc-modified anti-GPC3 antibody:

Example 1-1: Preparation of Fc cassettes for mutagenesis:

Fc-modified humanized anti-GPC3 antibodies having amion acid substitutions shown in the table below in the amino acid sequence of the H-chain shown in SEQ ID NO: 19. Fig. 1 shows the structure and preparation strategy of the Fc-modified antibodies of the invention.

V22	I332E
V209	S239D/A330L/I332E
V212	S239D/S298A/I332E
V922	S239D/K326T/I332E
V1608	S239D/S298A/K326T/I332E
V209nG1m(1)	S239D/A330L/I332E/D356E/L358M

Using primers shown by SEQ ID NO:1 to NO:9, Fc-mutation cassettes for constructing five types of Fc-modified antibodies named V22, V209, V212, V922 and V1608 were produced according to a PCR-Walking method. Specifically, primers commonF1 and commonR1 were used for V22, V209 and V922; and primers 212-F1 and 212-F1 were used for V212 and V1608. A first-stage PCR was carried out in a PCR reaction solution mentioned below:

x10 KOD buffer 5 μ l, dNTPs and MgCl₂ 5 μ l and 2 μ l, respectively, (attached to KOD polymerase, Toyobo) were mixed. The primer combination as above (20 μ mole/l,

1 μ l each), dH₂O 35.5 μ l, and 5 units/ μ l KOD polymerase 0.5 μ l were added to make 50 μ l in total. PCR was carried out under the condition mentioned below.

96°C 1 min; (98°C 15 sec; 65°C 2 sec; 74°C 15 sec) x 2 cycles; 74°C 30 sec; 4°C.

One microliter of the first stage-amplified product was taken out and used in the next, second-stage PCR reaction. Specifically, primers CommonF2 and 212-R2 were used for V22 and V212; primers CommonF2 and 209-R2 were used for V209; primers CommonF2 and 922-R2 were used for V922; and primers CommonF2 and 1608-R2 were used for V1608. The second-stage PCR was carried out in a PCR reaction solution mentioned below:

x10 KOD buffer 5 μ l, dNTPs and MgCl₂ 5 μ l and 2 μ l, respectively, (attached to KOD polymerase, Toyobo) were mixed. The primer combination as above (20 μ mole/l, 1 μ l each), 1 μ l of the first stage-amplified product as a template, dH₂O 35.5 μ l, and 5 units/ μ l KOD polymerase 0.5 μ l were added to make 51 μ l in total. PCR was carried out under the condition mentioned below.

96°C 1 min; (98°C 15 sec; 65°C 2 sec; 74°C 15 sec) x 5 cycles; 74°C 30 sec; 4°C.

One microliter of the second stage-amplified product was taken out and used in the next, third-stage PCR reaction. Specifically, primers CommonF3 and CommonR3 were used for V22, V209, V212, V922 and V1608, and the third-stage PCR was carried out in a PCR reaction solution mentioned below.

x10 KOD buffer 5 μ l, dNTPs and MgCl₂ 5 μ l and 2 μ l, respectively, (attached to KOD polymerase, Toyobo) were mixed. The primer combination as above (20 μ mole/l, 1 μ l each), 1 μ l of the second stage-amplified product as a template, dH₂O 35.5 μ l, and 5 units/ μ l KOD polymerase 0.5 μ l were added to it to make 51 μ l in total. Using this, PCR was carried out under the condition mentioned below.

96°C 1 min; (98°C 15 sec; 65°C 2 sec; 74°C 20 sec) x 35 cycles; 74°C 1 min; 4°C.

Each fragment obtained was subcloned into pBluescriptSK⁺ and its sequence was confirmed.

Forward primer: 212-F1 (SEQ ID NO: 1)

agttcaactggtacgtggacggcgtggaggtgcataatgccaaagacaagccggaggaggagcagtacaacgccacgtacc
gtgtggtcagcgtcc

Forward primer: commonF2 (SEQ ID NO: 2)

tctcccgaccctgaggtcacatgcgtgggtgggacgtgagccacgaagaccctgaggtcaagttcaactggtagctggac
ggcgtggagg

Forward primer: commonF3 (SEQ ID NO: 3)

gcacctgagctcctggggggaccggacgtcttctctcccccaaaaccaaggacaccctcatgatctcccgaccctga
ggcacatgcgtgg

Reverse primer: 212-R1 (SEQ ID NO: 4)

ggagacctgcacttgactccttgcattcagccagtcctggtgcaggacggtgaggacgctgaccacacggtagctggcgtt
gtactgctcc

Reverse primer: 209-R2 (SEQ ID NO: 5)

ggctgccctttggcttggagatggtttctctcgggcagtgaggaggcttggtagacctgcacttgactccttgcattca
gcc

Reverse primer: 212-R2 (SEQ ID NO: 6)

ggctgccctttggcttggagatggtttctctcgggggctgggagggttggtagacctgcacttgactccttgcattca
gcc

Reverse primer: 922-R2 (SEQ ID NO: 7)

ggctgccctttggcttggagatggtttctctcgggggctgggaggcggttggtagacctgcacttgactccttgcattc
agcc

Reverse primer: 1608-R2 (SEQ ID NO: 8)

ggctgccctttggcttggagatggtttctctcgggggctgggaggcgcttggtagacctgcacttgactccttgcattca
gcc

Reverse primer: commonR3 (SEQ ID NO: 9)

gagctccccgggatgggggcagggtgtacacctgtggtctcggggctgccctttggcttggagatggtttctctcgg

Example 1-2: Preparation of vector expressing Fc-modified anti-GPC3 antibody:

A vector for expressing the Fc-modified anti-GPC3 antibody of the invention was constructed based on a gene coding for a humanized anti-glypican-3 antibody previously prepared by the inventors (H-chain, SEQ ID NO: 10; L-chain, SEQ ID NO: 11), which is referred to as "wild-type" in the following Examples.

The amino acid sequences of the H-chain variable region and L-chain variable region of the wild-type humanized anti-GPC3 antibody are shown in SEQ ID NO: 21

(ver.k) and SEQ ID NO: 22 (ver.a), respectively. The CDR sequences of the wild-type humanized anti-GPC3 antibody are shown below.

H-chain

CDR1 DYEMH (SEQ ID NO: 23)

CDR2 ALDPKTGDTAYSQKFKG (SEQ ID NO: 24)

CDR3 FYSYTY (SEQ ID NO: 25)

L-chain

CDR1 RSSQSLVHSNGNTYLH (SEQ ID NO: 26)

CDR2 KVSNRFS (SEQ ID NO: 27)

CDR3 SQNTHVPPT (SEQ ID NO: 28)

Using the anti-human GPC3 antibody H-chain gene shown by SEQ ID NO:10 as a template, and using a primer of SEQ ID NO:11 and a primer of SEQ ID NO:12 with a SacI site previously introduced as silent mutation, PCR was carried out under the condition mentioned below.

x10 KOD buffer 5 µl, dNTPs and MgCl₂ 5 µl and 2 µl, respectively, (attached to KOD polymerase, Toyobo) were mixed. The primer combination as above (20 µmole/l, 1 µl each), 1 µl of GPC3 antibody H-chain gene as a template, dH₂O 34.5 µl, and 5 units/µl KOD polymerase 0.5 µl were added to make 50 µl in total. PCR was carried out under the condition mentioned below.

96°C 1 min; (98°C 15 sec; 65°C 2 sec; 74°C 30 sec) x 35 cycles; 74°C 30 sec; 4°C.

The fragment obtained was introduced into the SmaI site of pBluescriptSK⁺ (pB-Sacless), in which the SacI site had been previously filled up with a DNA blunting kit (Takara Bio), and its sequence was confirmed (pB-GPCSacmt). Next, from a vector containing an anti-GPC3 antibody H-chain gene shown by SEQ ID NO:10, an SmaI-BamHI fragment of about 290 bp, corresponding to the C-terminal sequence of anti-human GPC3 antibody H-chain, was cut out, and introduced into the corresponding site of pB-GPCSacmt (pB-GPCSacmtC). Next, the Fc-mutation cassette of V22, V209, V212, V922 or V1608 produced in Example 1-1 was introduced into the SacI-SmaI site of pB-GPCSacmtC, and the sequence of pB-GPCSacmtC was confirmed. Further, for completing construction of the mutated H-chain, an EcoRI-NheI fragment of about 415

bp of the GPC3 antibody H-chain gene shown by SEQ ID NO:10 was ligated with it to obtain a gene coding for Fc-mutated H-chain.

The resultant gene coding for a mutated H-chain was cleaved with EcoRI-NotI, and introduced into the corresponding site of an animal cell expression vector pCXND3 (pC-aGPCh). Next, a fragment of about 3.1 kb, containing an anti-GPC3 antibody L-chain gene shown by SEQ ID NO:13 and a promoter region, was cleaved with HindIII, and ligated with the corresponding site of pC-aGPCh to obtain an anti-GPC3 antibody expression vector (pC-aGPChI). The vector pC-aGPChI to V22, V209, V212, V922 and V1608 was designated as pC-aGPChI(22), pC-aGPChI(209), pC-aGPChI(212), pC-aGPChI(922) and pC-aGPChI(1608), respectively.

The amino acid sequence of the H chain of V22, V209, V212, V922 and V1608 are shown in V22 (SEQ ID NO: 29), V209 (SEQ ID NO: 30), V212 (SEQ ID NO: 31), V922 (SEQ ID NO: 32) and V1608 (SEQ ID NO: 33), respectively. The amino acid sequence of the CH2-CH3 domain of V22, V209, V212, V922 and V1608 are shown in V22 CH2-CH3 domain (SEQ ID NO: 34), V209 CH2-CH3 domain (SEQ ID NO: 35), V212 CH2-CH3 domain (SEQ ID NO: 36), V922 CH2-CH3 domain (SEQ ID NO: 37) and V1608 CH2-CH3 domain (SEQ ID NO: 38), respectively.

anti-human GPC3 antibody H-chain (SEQ ID NO: 10)

GAATTCCACCATGGACTGGACCTGGAGGTTCTCTTTGTGGTGGCAGCAGCTA
CAGGTGTCCAGTCCCAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAA
GCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACC
GACTATGAAATGCACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGA
TGGGAGCTCTTGATCCTAAACTGGTGATACTGCCTACAGTCAGAAGTTCAA
GGGCAGAGTCACGCTGACCGCGGACAAATCCACGAGCACAGCCTACATGGA
GCTGAGCAGCCTGACATCTGAGGACACGGCCGTGTATTACTGTACAAGATTC
TACTCCTATACTTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAG
CACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTG
GGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT
GACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCC

CTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCC
AGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACCTC
ACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTT
CCTCTTCCCCCCTAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG
AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA
CCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGC
CCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACC
AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACA
AGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC
TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
TAAGCGGCCGCGGATCC

Forward primer: NS-F(SEQ ID NO: 11)

gctagcaccaagggcccatcggtcttccccctggcaccctctcc

Reverse primer: NS-R(SEQ ID NO: 12)

gagctcaggtgctgggcacggtgggcatgtgtgagttttgtcac

anti-human GPC3 antibody L-chain (SEQ ID NO: 13)

AAGCTTGCATGCCTGCAGGTGCACTCTAGAGGATCCGTCGACATTGATTATTG
ACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATAT
GGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCCTGGCTGACCGCCC
AACGACCCCCGCCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC
CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACG
TCAATGACGGTAAATGGCCCCGCCTGGCATTATGCCCAGTACATGACCTTATG

GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGG
TCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCA
CCCCAATTTTGTATTTATTTATTTTAAATTATTTTGTGCAGCGATGGGGGCG
GGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCG
GGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT
CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAG
CGAAGCGCGCGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCC
GCTCCGCCGCGCCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTC
CCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGGCTGTAATTAGCGCT
TGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGG
CTCCGGGAGGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGT
GTGTGTGCGTGGGGAGCGCCGCGTGCGGCTCCGCGCTGCCCGGCGGCTGTGA
GCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCAGTGTGCGCGAGGGG
AGCGCGGCCGGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAAC
AAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGC
GCGTCGGTCGGGCTGCAACCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGC
ACGGCCCCGGCTTCGGGTGCGGGGCTCCGTACGGGGCGTGCGCGGGGGCTCGC
CGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCC
GCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCCGGAGCGC
CGGCGGCTGTGAGGCGCGGCGAGCCGAGCCATTGCCTTTTATGGTAATCG
TGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGTGCGGAGCCGAAAT
CTGGGAGGGCGCCGCCGACCCCCCTAGCGGGCGCGGGGCGAAGCGGTGCG
GCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCC
GCCGTCCCCTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTGC
CTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCG
GCTCTAGAGCCTCTGCTAACCATGTTTCATGCCTTCTTCTTTTCTACAGCTCC
TGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATTTTGGCAAAGAATTCCTC
GAGCCACCATGAGGCTCCCTGCTCAGCTCCTGGGGCTGCTAATGCTCTGGGTC
TCTGGATCCAGTGGGGATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGT
CACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGATCTAGTCAGAGCCTTGTA
ACAGTAATAGGAACACCTATTACATTGGTACCTGCAGAAGCCAGGGCAGTC

TCCACAGCTCCTGATCTATAAAGTTTCCAACCGATTTTCTGGGGTCCCTGACA
 GGTTCAAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT
 GGAGGCTGAGGATGTTGGGGTTTATTACTGCTCTCAAAATACACATGTTCCCTC
 CTACGTTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTGGCTGCACC
 ATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCT
 CTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTG
 GAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACACAGAG
 CAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGC
 AAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAG
 GGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTGATAAG
 TCGAGGTGAGGAATTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGT
 GGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCT
 CTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGG
 CTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCT
 CTCCTCGGAAGGACATATGGGAGGGCAAATCATTTAAACATCAGAATGAG
 TATTTGGTTTAGAGTTTGGCAACATATGCCCATATGCTGGCTGCCATGAACAA
 AGGTTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCCCCTGCTGTCCAT
 TCCTTATTCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATATTTGT
 TTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAG
 CCAGATTTTTCCTCCTCTCCTGACTACTCCAGTCATAGCTGTCCCTCTTCTCT
 TATGGAGATCCCTCGACCTGCAGCCCAAGCTT

Example 1-3: Production of V209 nGlm(1) allotype:

For obtaining an nGlm(1) allotype of V209, a Glm(1) allotype thereof, a cassette for nGlm(1) allotype was formed. Specifically, using forward primer HerSmaF and reverse primer HerNotR shown by SEQ ID NO: 14 and NO:15, and using, as a template, the anti-GPC3 antibody H-chain gene shown by SEQ ID NO:10 and produced in Example 1-2, PCR was carried out under the condition mentioned below.

x10 KOD buffer 5 μ l, dNTPs and $MgCl_2$ 5 μ l and 2 μ l, respectively, (attached to KOD polymerase, Toyobo) were mixed. The primer combination as above (20 μ mol/l, 1 μ l each), GPC3 antibody H-chain gene 1 μ l, dH_2O 34.5 μ l, and 5 units/ μ l KOD

polymerase 0.5 µl were added to make 50 µl in total. PCR was carried out under the condition mentioned below.

96°C 1 min; (98°C 15 sec; 65°C 2 sec; 74°C 30 sec) x 35 cycles; 74°C 30 sec; 4°C.

The fragment obtained was subcloned into pBluescriptSK⁺ (pBher), and its sequence was confirmed. Next, an SmaI-NotI fragment of about 290 bp was cut out from pC-aGPChl(209) described in Example 1-2. On the other hand, SmaI-NotI fragment was cut out from pBher in the same manner, and the fragment of about 290 bp was introduced into the corresponding site of pC-aGPChl(209) for substitution to obtain a nGlm(1) allotype expression vector (pC-aGPChl(209Her)).

Forward primer: HerSmaF (SEQ ID NO: 14)

gggaggagatgaccaagaaccagggtcacctgacctgcc

Reverse primer: HerNotR (SEQ ID NO: 15)

tttgcgccgcttatcattaccgagacaggagaggctc

Example 2: Preparation of Fc-modified anti-GPC3 antibody:

Example 2-1: Expression of Fc-modified anti-GPC3 antibody in CHO cells:

Ten microliters of Fc-modified anti-GPC3 antibody expression vector pC-aGPChl(22), pC-aGPChl(209), pC-aGPChl(212), pC-aGPChl(922), pC-aGPChl(1608) or pC-aGPChl(209Her) was cleaved with PvuI to give a linear DNA. This was introduced into 2 x 10⁶/0.6 ml PBS(-) of CHO cells (strain DXB11S) according to an electroporation method under a condition of 1.5 kV and 25 µF. The cells were incubated in a 8 % CO₂ incubator at 37°C. The cells were screened in CHO-S-SFMII medium (Invitrogen) containing 400 µg/ml of geneticin. Selected cells were inoculated into a CHO-S-SFMII medium containing 400 µg/ml geneticin in a 96-well plate at 0.4 cells/100 µl/well, and the cells were cloned according to a limiting dilution method. The culture supernatant was analyzed with BIACORE 3000. The antigen was quantified using a chip with fused protein GST-GPC3 (antigen GST and human glypican-3 shown by SEQ ID NO:16) immobilized thereon, and high-expression cells were selected.

Amino acid sequence of GPC3 peptide (SEQ ID NO: 16)

AELAYDLVDVDDAPGNSQQATPKDNEISTFHNLGNVHSPLK

Example 2-2: Purification of Fc-modified anti-GPC3 antibody:

The culture supernatant of CHO cells expressing Fc-modified humanized glypican antibody was applied to an rProtein A Sepharose Fast Flow column equilibrated with 150 mM NaCl-containing 10 mM citrate-phosphate buffer (pH 7.5). The column was washed with the same buffer, 1 M NaCl-containing 10 mM citrate-phosphate buffer (pH 7.5), then 10 mM citrate-phosphate buffer (pH 7.5), and the protein adsorbed to the column was eluted out with 20 mM acetic acid. To the 20 mM acetic acid fraction containing Fc-modified humanized anti-glypican antibody, 1 M tris-HCl buffer (pH 8.5) was added to adjust pH of from 5 to 6, and was filtered through a 0.22 μ m filter. An equivalent amount of MilliQ water was added to the thus-filtered fraction, and applied to SP Sepharose Fast Flow column equilibrated with 20 mM acetate buffer (pH 6.0). The column was washed with the same buffer, and then the protein adsorbed to the column was eluted out with 20 mM NaCl-containing 20 mM acetate buffer (pH 6.0) to obtain a purified fraction of Fc-modified humanized anti-glypican antibody.

Fig. 2 shows the result of SDS-PAGE (polyacrylamide gel electrophoresis) of a purified Fc-modified humanized anti-glypican antibody of the invention in a known method (Nature, 227, 680, 1970, hereby incorporated by reference in its entirety) to analyze the molecular weight and the degree of purification of the antibody. Each purified Fc-modified humanized anti-glypican antibody provided a single band at a molecular weight of about 150 kDa under a non-reducing condition and provided two bands at about 50 kDa and about 25 kDa under a reducing condition. These molecular weights substantially agree with those presumed from the nucleotide sequence of the H-chain and L-chain cDNAs of the antibody, and further agree with the report that an IgG-type antibody has a molecular weight of about 150 kDa under a non-reducing condition, and an H-chain having a molecular weight of about 50 kDa and an L-chain having a molecular weight of about 25 kDa under a reducing condition, where its intramolecular disulfide bond is cleaved (Antibodies, Chapter 14, Monoclonal Antibodies, hereby incorporated by reference in its entirety). It has been confirmed that each Fc-modified humanized anti-glypican antibody was expressed as an antibody molecule having a correct structure and was purified as such.

Fig. 3 shows a chromatogram of a purified Fc-modified humanized anti-glypican-3 antibody analyzed through a gel permeation column (Superdex 200 PC3.2/30, by GE Amersham Biosciences).

Example 3: Measurement of ADCC activity of Fc-modified anti-GPC3 antibody:

Example 3-1: cDNA cloning of human glypican-3 (GPC3):

A full-length cDNA coding for human GPC3 was amplified through PCR using Advantage2 kit (CLONETECH) and, as a template, 1st strand cDNA having been prepared from colon cancer cell line Caco2 in an ordinary manner. Specifically, 50 μ l of a reaction solution containing 2 μ l of Caco2-derived cDNA, 1 μ l of sense primer (GATATC-ATGGCCGGGACCGTGCGCACCGCGT, SEQ ID NO: 17), 1 μ l of antisense primer (GCTAGC-TCAGTGCACCAGGAAGAAGAAGCAC, SEQ ID NO: 18), 5 μ l of Advantage2 10xPCR buffer, 8 μ l of dNTX mix (1.25 mM) and 1.0 μ l of Advantage polymerase Mix, was subjected to 35 cycles of 94°C 1 min; 63°C 30 sec; 68°C 3 min. The PCR amplified product was inserted into a TA vector pGEM-Teasy by the use of pGEM-T Easy Vector System I (Promega). The sequence of the product was confirmed using ABI3100 DNA sequencer. In this way, cDNA coding for the full length of human GPC3 was isolated. The nucleotide sequence of human GPC3 gene is shown in SEQ ID NO:19, and the amino acid sequence of human GPC3 protein is shown in SEQ ID NO:20.

Example 3-2: Preparation of human hepatic cancer cell line (SK-03)expressing full-length GPC3:

To obtain a cell line for evaluating the biological activity of anti-GPC3 antibody, a human hepatic cell line capable of expressing a full-length GPC3 was established.

One μ g of full-length human GPC3 gene expression vector treated with PvuI was mixed with 2 μ l of FuGENE (Roche) to form a complex, and then this was added to SK-HEP-1 cells (purchased from ATCC) for gene introduction. The cells were incubated in a CO₂ incubator for 24 hours, and then, GPC3-expressing cells were selected using Dulbecco MEM (D-MEM, by SIGMA) containing geneticin (Invitrogen) at a final

concentration of 1 mg/ml and 10 % FBS. The thus-obtained geneticin-resistant colonies were collected, and the cells were cloned according to a limiting dilution method. The expression of human GPC3 in each cell clone was determined by flow cytometry using chimera GC33 antibody and FITC-labeled goat anti-human IgG antibody (ICN) to obtain a stable expression cell line SK-03 was obtained.

Example 3-3: Measurement of ADCC activity with human peripheral blood-derived PBMC:

Example 3-3-1: Preparation of human PBMC solution:

Heparin-added peripheral blood was collected from a healthy person, diluted 2-fold with PBS(-) and overlaid on Ficoll-PaqueTM PLUS (Amersham). After centrifugation (500 x g, 30 minutes, 20°C), the interlayer of a monocyte fraction was collected. The monocytes were washed three times and suspended in 10 % FBS/RPMI to prepare a human PBMC solution.

Example 3-3-2: Preparation of target cells:

SK-03 cells were maintained in D-MEM medium (SIGMA) containing 1 mg/ml of geneticin and 10 % FBS (ThermoTrace). The cells were peeled from the dish using Cell Dissociation Buffer (Invitrogen), and transferred to each well of a 96-well U-bottomed plate (Falcon) at 1×10^4 cells/well, and incubated for 1 day. After the incubation, 5.55 MBq of Chromium-51 was added and the cells were further incubated in a 5 % CO₂ incubator at 37°C for 4 hours. The cells were washed once with the medium, and suspended in 50 µl of 10 % FBS/RPMI1640 medium to prepare target cells.

Example 3-3-3: Chromium release test (ADCC activity):

Fifty µl of an antibody solution prepared to have a predetermined concentration was added to the target cells, and reacted at room temperature for 15 minutes. Next, 100 µl of the human PBMC solution was added (5×10^5 cells/well), and centrifuged, and then incubated in a 5 % CO₂ incubator at 37°C for 4 hours. After the incubation, the plate was centrifuged, and the radioactivity of 100 µl of the culture supernatant was counted with a

gamma counter. The specific chromium release ratio of the sample was obtained according to the following formula:

$$\text{Specific Chromium Release Ratio (\%)} = (A - C) \times 100 / (B - C)$$

wherein A indicates a mean value of the radioactivity (cpm) in each well; B indicates a mean value of the radioactivity (cpm) of each well, in which 100 μ l of aqueous 2 % NP-40 solution (Nonidet P-40, Code No. 252-23, by Nacalai Tesque) and 50 μ l of 10 % FBS/RPMI medium were added to the target cells; C indicates a mean value of the radioactivity (cpm) of each well, in which 150 μ l of 10 % FBS/RPMI medium was added to the target cells.

The experiment was carried out in triplicate, and the mean value of the ADCC activity (%) of the sample was calculated.

The results are shown in Fig. 4. The Fc-modified humanized anti-glypican antibodies V22, V209, V922, V1608 and V209(nGlm(1)) all had enhanced ADCC activity compared to the wild-type antibody (WT). Of those, the activity of V22 was lower than that of the others, but there was found little difference in the activity between V209, V922, V1608 and V209(nGlm(1)).

Example 3-4: Measurement of ADCC activity using mouse marrow-derived effector cells:

Example 3-4-1: Preparation of mouse marrow-derived effector cell suspension:

Marrow cells were collected from the thigh bone of an SCID mouse (from Nippon Clea, male, 10 weeks old), and suspended in 10 % FBS/RPMI1640 medium at a density of 5×10^5 cells/ml. Mouse GM-CSF (Pepro Tech) and human IL-2 (Pepro Tech) were added at a final concentration of 10 ng/ml and 50 ng/ml, respectively. The cells were incubated in a 5 % CO₂ incubator at 37°C for 5 days. After the incubation, the cells were peeled with a scraper, washed once with the medium, and suspended in 10 % FBS/RPMI1640 medium at a density of 5×10^6 cells/ml to prepare a mouse marrow-derived effector cell suspension.

Example 3-4-2: Preparation of target cells:

Human hepatic cancer cells HepG2 (purchased from ATCC) were maintained in RPMI1640 medium (SIGMA) containing 10 % FBS (Thermo Trace). The cells were peeled from the dish using Cell Dissociation Buffer (Invitrogen), and transferred to each well of a 96-well U-bottomed plate (Falcon) at a density of 1×10^4 cells/well, and incubated for 1 day. After the incubation, 5.55 MBq of Chromium-51 was added and the cells were further incubated in a 5 % CO₂ incubator at 37°C for 4 hours. The cells were washed once with the medium, and suspended in 50 µl of 10 % FBS/RPMI1640 medium to prepare target cells.

Example 3-4-3: Chromium release test (ADCC activity):

Fifty µl of an antibody solution prepared to have a predetermined concentration was added to the target cells, and reacted at room temperature for 15 minutes. Next, 100 µl of the mouse marrow-derived effector cell suspension was added (5×10^5 cells/well), and centrifuged, and then incubated in a 5 % CO₂ incubator at 37°C for 4 hours. After the incubation, the plate was centrifuged, and the radioactivity of 100 µl of the culture supernatant was counted with a gamma counter. The specific chromium release ratio of the sample was obtained according to the following formula:

$$\text{Specific Chromium Release Ratio (\%)} = (A - C) \times 100 / (B - C)$$

wherein A indicates a mean value of the radioactivity (cpm) in each well; B indicates a mean value of the radioactivity (cpm) of each well, in which 100 µl of aqueous 2 % NP-40 solution (Nonidet P-40, Code No. 252-23, by Nacalai Tesque) and 50 µl of 10 % FBS/RPMI medium were added to the target cells; C indicates a mean value of the radioactivity (cpm) of each well, in which 150 µl of 10 % FBS/RPMI medium was added to the target cells.

The experiment was carried out in triplicate, and the mean value of the ADCC activity (%) of the sample was calculated.

The results are shown in Fig. 5. The Fc-modified humanized anti-glypican antibodies V22, V209 and V1608 all had enhanced ADCC activity compared to the wild-type antibody (WT).

Industrial Utility

The Fc-modified humanized anti-glypican-3 antibody is useful in treating cancers, such as hepatic cancer.

WHAT IS CLAIMED IS:

1. An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region.
2. An anti-glypican-3 antibody in which one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues.
3. An anti-glypican-3 antibody selected from the group consisting of:
 - (a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with another amino acid residue;
 - (b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with other amino acid residues;
 - (c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with other amino acid residues;
 - (d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with other amino acid residues;
 - (e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with other amino acid residues.
4. An anti-glypican-3 antibody selected from the group consisting of:
 - (a) an anti-glypican-3 antibody having glutamic acid at the position 332 of the Fc region ;
 - (b) an anti-glypican-3 antibody having aspartic acid at the position 239, leucine at the position 330, and glutamic acid at the position 332 of the Fc region;

- (c) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, and glutamic acid at the position 332 of the Fc region;
- (d) an anti-glypican-3 antibody having aspartic acid at the position 239, threonine at the position 326, and glutamic acid at the position 332 of the Fc region;
- (e) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, glutamic acid at the position 326, and glutamic acid at the position 332 of the Fc region.

5. An anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with glutamic acid;
- (b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with aspartic acid, leucine, and glutamic acid, respectively;
- (c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with aspartic acid, alanine, and glutamic acid, respectively;
- (d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with aspartic acid, threonine, and glutamic acid, respectively;
- (e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with aspartic acid, alanine, glutamic acid, and glutamic acid, respectively.

6. An anticancer agent comprising the anti-glypican-3 antibody as claimed in any one of Claims 1-5 and a pharmaceutically acceptable carrier.

7. A method of treating a patient with cancer comprising administering to the patient the anticancer agent as claimed in Claim 6.

8. A method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

- (i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody in which one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 of the Fc region are substituted by other amino acid residues; and
- (ii) isolating the antibody from the culture.

9. A method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

- (i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody selected from the group consisting of:
 - (a) an anti-glypican-3 antibody in which the amino acid residue at the position 332 of the Fc region is substituted with another amino acid residue;
 - (b) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 330 and 332 of the Fc region are substituted with other amino acid residues;
 - (c) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298 and 332 of the Fc region are substituted with other amino acid residues;
 - (d) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 326 and 332 of the Fc region are substituted with other amino acid residues;
 - (e) an anti-glypican-3 antibody in which the amino acid residues at the positions 239, 298, 326 and 332 of the Fc region are substituted with other amino acid residues; and
- (ii) isolating said antibody from the culture.

10. A method for producing an anti-glypican-3 antibody with enhanced cytotoxicity comprising:

(i) culturing a host cell engineered to express a polynucleotide coding for an anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody having glutamic acid at the position 332 of the Fc region;
 - (b) an anti-glypican-3 antibody having aspartic acid at the position 239, leucine at the position 330, and glutamic acid at the position 332 of the Fc region;
 - (c) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, and glutamic acid at the position 332 of the Fc region;
 - (d) an anti-glypican-3 antibody having aspartic acid at the position 239, threonine at the position 326, and glutamic acid at the position 332 of the Fc region;
 - (e) an anti-glypican-3 antibody having aspartic acid at the position 239, alanine at the position 298, glutamic acid at the position 326, and glutamic acid at the position 332 of the Fc region; and
- (ii) isolating said antibody from the culture.


11. An anti-glypican-3 antibody selected from the group consisting of:

- (a) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 34;
- (b) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 35;
- (c) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 36;
- (d) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 37; and
- (e) an anti-glypican-3 antibody having the CH2-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 38.



Fig.1

Fig.2






Fig.3




Fig.4




Fig.5

SEQUENCE LISTING

<110> Chugai Seiyaku Kabushiki Kaisha et al.

<120> Anti-Glypican 3 Antibody

<130> 19672-002WO1

<150> US 11/251,561

<151> 2005-10-14

<160> 38

<170> PatentIn version 3.1

<210> 1

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 1

agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg 60
agcagtacaa cgccacgtac cgtgtgggtca gcgtcc 96

<210> 2

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 2

tctcccgac ccctgaggtc acatgcgtgg tgggtggacgt gagccacgaa gaccctgagg 60
tcaagttcaa ctggtacgtg gacggcgtgg agg 93

<210> 3

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 3

gcacctgagc tcctgggggg accggacgtc ttctcttcc ccccaaaacc caaggacacc 60
ctcatgatct cccggacccc tgaggtcaca tgcgtgg 97

<210> 4

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 4

ggagaccttg cacttgact ccttgccatt cagccagtc tggcgcagga cggcgaggac 60
gctgaccaca cggcagctgg cgttgacttg ctcc 94

<210> 5

<211> 91

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 5

ggctgccctt tggctttgga gatggttttc tcctcgggca gtgggagggc tttgttggag 60
accttgcaact tgtactcctt gccattcagc c 91

<210> 6

<211> 91

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 6

ggctgccctt tggctttgga gatggttttc tcctcggggg ctgggagggc tttgttggag 60

accttgcaact tgtactcctt gccattcagc c

91

<210> 7

<211> 91

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 7

ggctgccctt tggctttgga gatgggttttc tcctcggggg ctgggagggc ggtgttggag 60

accttgcaact tgtactcctt gccattcagc c 91

<210> 8

<211> 91

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 8

ggctgccctt tggctttgga gatgggttttc tcctcggggg ctgggagggc ctcgttggag 60

accttgcaact tgtactcctt gccattcagc c 91

<210> 9

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 9

gagctccccg ggatgggggc aggggtgtaca cctgtgggtc tcggggctgc cctttggctt 60

tggagatggt tttctcctcg g 81

<210> 10

<211> 1422

<212> DNA

<213> Artificial Sequence

<220>

<223> humanized antibody H-chain

<400> 10

```

gaattccacc atggactgga cctggagggt cctctttgtg gtggcagcag ctacaggtgt    60
ccagtcccag gtgcagctgg tgcagtctgg agctgagggt aagaagcctg gggcctcagt    120
gaaggctccc tgcaaggctt ctggatacac cttcacccgac tatgaaatgc actgggtgcg    180
acaggcccct ggacaagggc ttgagtggat gggagctctt gatcctaaaa ctggtgatac    240
tgcctacagt cagaagttca agggcagagt cacgctgacc gcggacaaat ccacgagcac    300
agcctacatg gagctgagca gcctgacatc tgaggacacg gccgtgtatt actgtacaag    360
attctactcc tatacttact ggggccaggg aaccctggtc accgtctcct cagctagcac    420
caagggccca tcggtcttcc ccctggcacc ctctccaag agcacctctg ggggcacagc    480
ggccctgggc tgcttggtca aggactactt ccccgaaacc gtgacgggtg cgtggaactc    540
aggcgccctg accagcgggc tgcacacctt cccggctgtc ctacagtcct caggactcta    600
ctccctcagc agcgtggtga ccgtgccctc cagcagcttg ggcaccaga cctacatctg    660
caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaactctg    720
tgacaaaact cacacatgcc caccgtgccc agcacctgaa ctctggggg gaccgtcagt    780
cttctcttcc ccccaaaaac ccaaggacac cctcatgatc tcccggacc ctgaggtcac    840
atgcgtggtg gtggacgtga gccacgaaga ccctgagggt aagttcaact ggtacgtgga    900
cggcgtggag gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta    960
ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa   1020
gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa   1080
agggcagccc cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa   1140
gaaccaggtc agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga   1200
gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc   1260
cgacggctcc ttcttctct acagcaagct caccgtggac aagagcaggt ggcagcaggg   1320
gaacgtcttc tcatgtccg tgatgcatga ggctctgcac aaccactaca cgcagaagag   1380
cctctccctg tctccgggta aatgataagc ggccgcggat cc                               1422

```

<210> 11

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 11

```

gctagcacca agggcccatc ggtcttcccc ctggcaccct cctcc

```

45

<210> 12

<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 12
gagctcaggt gctgggcacg gtgggcatgt gtgagttttg tcac 44

<210> 13
<211> 3067
<212> DNA
<213> Artificial Sequence

<220>
<223> Humanized antibody L-chain

<400> 13
aagcttgcat gcctgcaggt cgactctaga ggatccgctg acattgatta ttgactagtt 60
attaatagta atcaattacg gggtcattag ttcataagccc atatatggag ttccgcgtta 120
cataacttac ggtaaattggc ccgcctggct gaccgcccac cgacccccgc ccattgacgt 180
caataatgac gtatgttccc atagtaacgc caatagggac tttccattga cgtcaatggg 240
tggagtatatt acggtaaact gcccacttgg cagtacatca agtgtatcat atgccaagta 300
cgccccctat tgacgtcaat gacggtaaatt ggcccgctg gcattatgcc cagtacatga 360
ccttatggga ctttcctact tggcagtaca tctacgtatt agtcatcgct attaccatgg 420
tcgaggtgag cccacgcttc tgcctcactc tccccatctc cccccctcc ccacccccaa 480
ttttgtattt atttattttt taattatttt gtgcagcgat gggggcgagg gggggggggg 540
ggcgcgcgcc aggcggggcg gggcgggggc aggggcgggg cggggcgagg cggagaggtg 600
cggcggcagc caatcagagc ggcgcgctcc gaaagtttcc ttttatggcg aggcggcggc 660
ggcggcggcc ctataaaaag cgaagcgcgc ggcggggcgg agtcgctgcg cgctgccttc 720
gccccgtgcc ccgctccgcc gccgcctcgc gccgcccgcc ccggtctga ctgaccgcgt 780
tactcccaca ggtgagcggg cgggacggcc cttctcctcc gggctgtaat tagcgcttgg 840
tttaatgacg gcttggttct tttctgtggc tgcgtgaaag ccttgagggg ctccgggagg 900
gccctttgtg cggggggagc ggctcggggg gtgcgtgcgt gtgtgtgtgc gtggggagcg 960
ccgcgtgcgg ctccgcgctg cccggcggtc gtgagcgtc cgggcgcggc gcggggcttt 1020
gtgcgctccg cagtgtgcgc gaggggagcg cggccggggg cggcgccccg cggcgcgggg 1080
ggggctgcga ggggaacaaa ggctgcgtgc ggggtgtgtg cgtggggggg tgagcagggg 1140
gtgtgggcgc gtcggtcggg ctgcaacccc ccctgcaccc ccctccccga gttgctgagc 1200
acggccccgc ttcgggtgcg gggctccgta cggggcggtg cgcggggctc gccgtgccgg 1260
gcgggggggtg gcggcaggtg ggggtgccgg gcggggcggg gccgcctcgg gccggggagg 1320
gctcggggga ggggcgcggc ggcccccgga gcgcggcgcg ctgtcgaggc gcggcgagcc 1380

```

gcagccattg ccttttatgg taatcgtgcg agagggcgca gggacttcct ttgtcccaaa 1440
tctgtgcgga gccgaaatct gggaggcgcc gccgcacccc ctctagcggg cgcggggcgca 1500
agcggtgcg cgccggcagg aaggaaatgg gcggggaggg ccttcgtgcg tcgccgcgcc 1560
gccgtccctt tctccctctc cagcctcggg gctgtccgcg gggggacggc tgccttcggg 1620
ggggacgggg cagggcgggg ttcggcttct ggcgtgtgac cggcggctct agagcctctg 1680
ctaaccatgt tcatgccttc ttctttttcc tacagctcct gggcaacgtg ctggttattg 1740
tgctgtctca tcattttggc aaagaattcc tcgagccacc atgaggctcc ctgctcagct 1800
cctggggctg ctaatgctct gggctctctg atccagtggg gatgttgatga tgactcagtc 1860
tccactctcc ctgcccgta cccctggaga gccggcctcc atctcctgca gatctagtca 1920
gagccttgta cacagtaata ggaacaccta ttacattgg tacctgcaga agccagggca 1980
gtctccacag ctctgatct ataaagtct caaccgattt tctggggctc ctgacagggtt 2040
cagtggcagt ggatcaggca cagattttac actgaaaatc agcagagtgg aggctgagga 2100
tggtgggggt tattactgct ctcaaaatac acatgttcct cctacgtttg gccaggggac 2160
caagctggag atcaaacgta cgggtggctgc accatctgtc ttcatcttcc cgccatctga 2220
tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag 2280
agaggccaaa gtacagtgga aggtggataa cgccctccaa tcgggtaact cccaggagag 2340
tgtcacagag caggacagca aggacagcac ctacagcctc agcagcacc tgacgctgag 2400
caaagcagac tacgagaaac acaaagtcta cgcctgcgaa gtcacccatc agggcctgag 2460
ctcggccgtc acaaagagct tcaacagggg agagtgttga taagtcgagg tcgaggaatt 2520
cactcctcag gtgcaggctg cctatcagaa ggtggtggct ggtgtggcca atgccctggc 2580
tcacaaatac cactgagatc tttttccctc tgccaaaaat tatggggaca tcatgaagcc 2640
ccttgagcat ctgacttctg gctaataaag gaaatttatt ttattgcaa tagtgtgttg 2700
gaattttttg tgtctctcac tcggaaggac atatgggagg gcaaatcatt taaaacatca 2760
gaatgagtat ttggtttaga gtttggcaac atatgccc atgctggctg ccatgaacaa 2820
aggttggcta taaagaggct atcagtatat gaaacagccc cctgctgtcc attccttatt 2880
ccatagaaaa gccttgactt gaggttagat tttttttata ttttgttttg tgttattttt 2940
ttctttaaca tccctaaaat tttccttaca tgttttacta gccagatttt tcctcctctc 3000
ctgactactc ccagtcatag ctgtccctct tctcttatgg agatccctcg acctgcagcc 3060
caagctt

```

3067

<210> 14
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 14
 gggaggagat gaccaagaac caggtcaccc tgacctgcc

39

<210> 15

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 15

tttgcgggccg cttatcattt acccgagac agggagaggc tc

42

<210> 16

<211> 40

<212> PRT

<213> Homo sapiens

<400> 16

Ala Glu Leu Ala Tyr Asp Leu Asp Val Asp Asp Ala Pro Gly Asn Ser

1

5

10

15

Gln Gln Ala Thr Pro Lys Asp Asn Glu Ile Ser Thr Phe His Asn Leu

20

25

30

Gly Asn Val His Ser Pro Leu Lys

35

40

<210> 17

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 17

gatatcatgg ccgggaccgt gcgcaccgcg t

31

<210> 18

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 18

gctagctcag tgcaccagga agaagaagca c

31

<210> 19

<211> 1743

<212> DNA

<213> Homo sapiens

<400> 19

atggccgggga	ccgtgcgcac	cgcgtgcttg	gtggtggcga	tgctgctcag	cttggacttc	60
ccgggacagg	cgcagcccc	gccgcgcgcg	ccggacgcca	cctgtcacca	agtcgcctcc	120
ttcttccaga	gactgcagcc	cggactcaag	tgggtgccag	aaactcccg	gccaggatca	180
gatttgcaag	tatgtctccc	taagggccca	acatgctgct	caagaaagat	ggaagaaaaa	240
taccaactaa	cagcacgatt	gaacatggaa	cagctgcttc	agtctgcaag	tatggagctc	300
aagttcttaa	ttattcagaa	tgctgcgggt	ttccaagagg	cctttgaaat	tgttgctcgc	360
catgccaaga	actacaccaa	tgccatgttc	aagaacaact	acccaagcct	gactccacaa	420
gcttttgagt	ttgtgggtga	atttttcaca	gatgtgtctc	tctacatctt	gggttctgac	480
atcaatgtag	atgacatgg	caatgaattg	tttgacagcc	tgtttccagt	catctatacc	540
cagctaata	g	g	g	g	g	600
gcaagacgtg	acctgaaagt	atgtgggaat	ttccccaa	g	g	660
aagtcactgc	aagtcactag	gatcttcctt	caggctctga	atcttggaat	tgaagtgatc	720
aacacaactg	atcacctgaa	gttcagtaag	gactgtggcc	gaatgctcac	cagaatgtgg	780
tactgctctt	actgccagg	actgatgatg	gttaaaccct	gtggcggtta	ctgcaatgtg	840
gtcatgcaag	gctgtatgg	aggtgtgggt	gagattgaca	agtactggag	agaatacatt	900
ctgtcccttg	aagaacttgt	gaatggcatg	tacagaatct	atgacatgga	gaacgtactg	960
cttgggtctct	tttcaacaat	ccatgattct	atccagtatg	tccagaagaa	tgcaggaaag	1020
ctgaccacca	ctattggcaa	gttatgtgcc	cattctcaac	aacgccaata	tagatctgct	1080
tattatcctg	aagatctctt	tattgacaag	aaagtattaa	aagttgctca	tgtagaacat	1140
gaagaaacct	tatccagccg	aagaaggga	ctaattcaga	agttgaagtc	tttcatcagc	1200
ttctatagt	ctttgcctgg	ctacatctgc	agccatagcc	ctgtggcgga	aaacgacacc	1260
ctttgctgga	atggacaaga	actcgtggag	agatacagcc	aaaaggcagc	aaggaatgga	1320
atgaaaaacc	agttcaatct	ccatgagctg	aaaatgaagg	gccctgagcc	agtggctcag	1380
caaattattg	acaaactgaa	gcacattaac	cagctcctga	gaacctatgc	tatgccccaa	1440
ggtagagttc	tggataaaaa	cctggatgag	gaagggtttg	aaagtggaga	ctgcggtgat	1500
gatgaagatg	agtgcatgtg	aggctctgg	gatggaatga	taaaagtga	gaatcagctc	1560
cgcttccttg	cagaactggc	ctatgatctg	gatgtggatg	atgcgcctgg	aaacagtcag	1620
caggcaactc	cgaaggacaa	cgagataagc	acctttcaca	acctcgggaa	cgttcattcc	1680
ccgctgaagc	ttctcaccag	catggccatc	tcggtgggtg	gcttcttctt	cctgggtgcac	1740
tga						1743

<210> 20

<211> 580

<212> PRT

<213> Homo sapiens

<400> 20

Met Ala Gly Thr Val Arg Thr Ala Cys Leu Val Val Ala Met Leu Leu
1 5 10 15
Ser Leu Asp Phe Pro Gly Gln Ala Gln Pro Pro Pro Pro Pro Pro Asp
20 25 30
Ala Thr Cys His Gln Val Arg Ser Phe Phe Gln Arg Leu Gln Pro Gly
35 40 45
Leu Lys Trp Val Pro Glu Thr Pro Val Pro Gly Ser Asp Leu Gln Val
50 55 60
Cys Leu Pro Lys Gly Pro Thr Cys Cys Ser Arg Lys Met Glu Glu Lys
65 70 75 80
Tyr Gln Leu Thr Ala Arg Leu Asn Met Glu Gln Leu Leu Gln Ser Ala
85 90 95
Ser Met Glu Leu Lys Phe Leu Ile Ile Gln Asn Ala Ala Val Phe Gln
100 105 110
Glu Ala Phe Glu Ile Val Val Arg His Ala Lys Asn Tyr Thr Asn Ala
115 120 125
Met Phe Lys Asn Asn Tyr Pro Ser Leu Thr Pro Gln Ala Phe Glu Phe
130 135 140
Val Gly Glu Phe Phe Thr Asp Val Ser Leu Tyr Ile Leu Gly Ser Asp
145 150 155 160
Ile Asn Val Asp Asp Met Val Asn Glu Leu Phe Asp Ser Leu Phe Pro
165 170 175
Val Ile Tyr Thr Gln Leu Met Asn Pro Gly Leu Pro Asp Ser Ala Leu
180 185 190
Asp Ile Asn Glu Cys Leu Arg Gly Ala Arg Arg Asp Leu Lys Val Phe
195 200 205
Gly Asn Phe Pro Lys Leu Ile Met Thr Gln Val Ser Lys Ser Leu Gln
210 215 220
Val Thr Arg Ile Phe Leu Gln Ala Leu Asn Leu Gly Ile Glu Val Ile
225 230 235 240
Asn Thr Thr Asp His Leu Lys Phe Ser Lys Asp Cys Gly Arg Met Leu
245 250 255
Thr Arg Met Trp Tyr Cys Ser Tyr Cys Gln Gly Leu Met Met Val Lys
260 265 270
Pro Cys Gly Gly Tyr Cys Asn Val Val Met Gln Gly Cys Met Ala Gly
275 280 285
Val Val Glu Ile Asp Lys Tyr Trp Arg Glu Tyr Ile Leu Ser Leu Glu
290 295 300

Glu Leu Val Asn Gly Met Tyr Arg Ile Tyr Asp Met Glu Asn Val Leu
 305 310 315 320
 Leu Gly Leu Phe Ser Thr Ile His Asp Ser Ile Gln Tyr Val Gln Lys
 325 330 335
 Asn Ala Gly Lys Leu Thr Thr Thr Ile Gly Lys Leu Cys Ala His Ser
 340 345 350
 Gln Gln Arg Gln Tyr Arg Ser Ala Tyr Tyr Pro Glu Asp Leu Phe Ile
 355 360 365
 Asp Lys Lys Val Leu Lys Val Ala His Val Glu His Glu Glu Thr Leu
 370 375 380
 Ser Ser Arg Arg Arg Glu Leu Ile Gln Lys Leu Lys Ser Phe Ile Ser
 385 390 395 400
 Phe Tyr Ser Ala Leu Pro Gly Tyr Ile Cys Ser His Ser Pro Val Ala
 405 410 415
 Glu Asn Asp Thr Leu Cys Trp Asn Gly Gln Glu Leu Val Glu Arg Tyr
 420 425 430
 Ser Gln Lys Ala Ala Arg Asn Gly Met Lys Asn Gln Phe Asn Leu His
 435 440 445
 Glu Leu Lys Met Lys Gly Pro Glu Pro Val Val Ser Gln Ile Ile Asp
 450 455 460
 Lys Leu Lys His Ile Asn Gln Leu Leu Arg Thr Met Ser Met Pro Lys
 465 470 475 480
 Gly Arg Val Leu Asp Lys Asn Leu Asp Glu Glu Gly Phe Glu Ser Gly
 485 490 495
 Asp Cys Gly Asp Asp Glu Asp Glu Cys Ile Gly Gly Ser Gly Asp Gly
 500 505 510
 Met Ile Lys Val Lys Asn Gln Leu Arg Phe Leu Ala Glu Leu Ala Tyr
 515 520 525
 Asp Leu Asp Val Asp Asp Ala Pro Gly Asn Ser Gln Gln Ala Thr Pro
 530 535 540
 Lys Asp Asn Glu Ile Ser Thr Phe His Asn Leu Gly Asn Val His Ser
 545 550 555 560
 Pro Leu Lys Leu Leu Thr Ser Met Ala Ile Ser Val Val Cys Phe Phe
 565 570 575
 Phe Leu Val His
 580

<210> 21

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody H-chain variable region

<400> 21

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115

<210> 22

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody L-chain variable region

<400> 22

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
85 90 95

Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 23

<211> 5

<212> PRT

<213> Mus musculus

<400> 23

Asp Tyr Glu Met His

1 5

<210> 24

<211> 17

<212> PRT

<213> Mus musculus

<400> 24

Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe Lys

1 5 10 15

Gly

<210> 25

<211> 6

<212> PRT

<213> Mus musculus

<400> 25

Phe Tyr Ser Tyr Thr Tyr

1 5

<210> 26

<211> 16

<212> PRT

<213> Mus musculus

<400> 26

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His

1 5 10 15

<210> 27

<211> 7

<212> PRT

<213> Mus musculus

<400> 27

Lys Val Ser Asn Arg Phe Ser

1 5

<210> 28

<211> 9

<212> PRT

<213> Mus musculus

<400> 28

Ser Gln Asn Thr His Val Pro Pro Thr

1 5

<210> 29

<211> 445

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody H-chain

<400> 29

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

20 25 30

Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val

130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala

145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
165 170 175
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
180 185 190
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
195 200 205
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
210 215 220
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
225 230 235 240
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
245 250 255
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
260 265 270
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
275 280 285
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
290 295 300
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
305 310 315 320
Val Ser Asn Lys Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys
325 330 335
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
340 345 350
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
370 375 380
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
385 390 395 400
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
405 410 415
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 30

<211> 445

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody H-chain

<400> 30

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
115 120 125
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
130 135 140
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
145 150 155 160
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
165 170 175
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
180 185 190
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
195 200 205
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
210 215 220
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu
225 230 235 240
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
245 250 255
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
260 265 270
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
275 280 285
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
290 295 300

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 305 310 315 320
 Val Ser Asn Lys Ala Leu Pro Leu Pro Glu Glu Lys Thr Ile Ser Lys
 325 330 335
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 340 345 350
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 355 360 365
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 370 375 380
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 385 390 395 400
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 405 410 415
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 420 425 430
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440 445

<210> 31

<211> 445

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody H-chain

<400> 31

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
 115 120 125
 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
 130 135 140
 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
 145 150 155 160
 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
 165 170 175
 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
 180 185 190
 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
 195 200 205
 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
 210 215 220
 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu
 225 230 235 240
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 245 250 255
 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 260 265 270
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 275 280 285
 Pro Arg Glu Glu Gln Tyr Asn Ala Thr Tyr Arg Val Val Ser Val Leu
 290 295 300
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 305 310 315 320
 Val Ser Asn Lys Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys
 325 330 335
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 340 345 350
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 355 360 365
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 370 375 380
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 385 390 395 400
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 405 410 415
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 420 425 430
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440 445

<210> 32
<211> 445
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized antibody H-chain

<400> 32
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
115 120 125
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
130 135 140
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
145 150 155 160
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
165 170 175
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
180 185 190
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
195 200 205
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
210 215 220
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu
225 230 235 240
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 260 265 270
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 275 280 285
 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 290 295 300
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 305 310 315 320
 Val Ser Asn Thr Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys
 325 330 335
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 340 345 350
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 355 360 365
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 370 375 380
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 385 390 395 400
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 405 410 415
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 420 425 430
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440 445

<210> 33

<211> 445

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized antibody H-chain

<400> 33

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
 50 55 60

Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
 115 120 125
 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
 130 135 140
 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
 145 150 155 160
 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
 165 170 175
 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
 180 185 190
 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
 195 200 205
 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
 210 215 220
 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu
 225 230 235 240
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 245 250 255
 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 260 265 270
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 275 280 285
 Pro Arg Glu Glu Gln Tyr Asn Ala Thr Tyr Arg Val Val Ser Val Leu
 290 295 300
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 305 310 315 320
 Val Ser Asn Glu Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys
 325 330 335
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 340 345 350
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 355 360 365
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 370 375 380
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 405 410 415
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 420 425 430
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440 445

<210> 34
 <211> 217
 <212> PRT
 <213> Homo sapiens

<400> 34
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 1 5 10 15
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 20 25 30
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 35 40 45
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 50 55 60
 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 65 70 75 80
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 85 90 95
 Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 100 105 110
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 115 120 125
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 130 135 140
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 145 150 155 160
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 165 170 175
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 180 185 190
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 195 200 205
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215

<210> 35
<211> 217
<212> PRT
<213> Homo sapiens

<400> 35
Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro Lys
1 5 10 15
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
20 25 30
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
35 40 45
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
50 55 60
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
65 70 75 80
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
85 90 95
Ala Leu Pro Leu Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
100 105 110
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
115 120 125
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
130 135 140
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
145 150 155 160
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
165 170 175
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
180 185 190
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
195 200 205
Lys Ser Leu Ser Leu Ser Pro Gly Lys
210 215

<210> 36
<211> 217
<212> PRT
<213> Homo sapiens

<400> 36
Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro Lys

1 5 10 15
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 20 25 30
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 35 40 45
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 50 55 60
 Gln Tyr Asn Ala Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 65 70 75 80
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 85 90 95
 Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 100 105 110
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 115 120 125
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 130 135 140
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 145 150 155 160
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 165 170 175
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 180 185 190
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 195 200 205
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215

<210> 37
 <211> 217
 <212> PRT
 <213> Homo sapiens

<400> 37
 Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro Lys
 1 5 10 15
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 20 25 30
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 35 40 45
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 50 55 60

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 65 70 75 80
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Thr
 85 90 95
 Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 100 105 110
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 115 120 125
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 130 135 140
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 145 150 155 160
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 165 170 175
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 180 185 190
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 195 200 205
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215

<210> 38
 <211> 217
 <212> PRT
 <213> Homo sapiens

<400> 38
 Ala Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro Lys
 1 5 10 15
 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 20 25 30
 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
 35 40 45
 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 50 55 60
 Gln Tyr Asn Ala Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 65 70 75 80
 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Glu
 85 90 95
 Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 100 105 110
 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu

115 120 125
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
130 135 140
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
145 150 155 160
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
165 170 175
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
180 185 190
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
195 200 205
Lys Ser Leu Ser Leu Ser Pro Gly Lys
210 215

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/047291 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/00 (2006.01)
C07K 16/18 (2006.01)

SUGO, Izumi [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 135, Komakado 1-chome, Gotemba-shi, Shizuoka 412-8513 (JP).

(21) International Application Number:

PCT/US2006/039682

(74) Agent: FRASER, Janis K., Ph.D., J.D.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(22) International Filing Date: 11 October 2006 (11.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11/251,561 14 October 2005 (14.10.2005) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 11/251,561 (CON)
Filed on 14 October 2005 (14.10.2005)

(71) Applicants (for all designated States except US):

CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543 (JP). XENCOR, INC. [US/US]; 111 West Lemon Avenue, Monrovia, California 91016 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LAZAR, Gregory Alan [US/US]; 3100 Riverside Drive #139, Los Angeles, California 90027 (US). DAHIYAT, Bassil I. [US/US]; 3829 Luna Court, Altadena, California 91001 (US). OKABE, Hisafumi [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 200, Kajiwarra, Kamakura-shi, Kanagawa 247-8530 (JP). SUGIMOTO, Masamichi [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 200, Kajiwarra, Kamakura-shi, Kanagawa 247-8530 (JP). IJIMA, Shigeyuki [JP/JP]; c/o Chugai Seiyaku Kabushiki Kaisha, 135, Komakado 1-chome, Gotemba-shi, Shizuoka 412-8513 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

21 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-GLYPICAN-3 ANTIBODY



(57) Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.

WO 2007/047291 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/039682

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/395 C07K16/18 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 411 118 A1 (ABURATANI HIROYUKI [JP]; CHUGAI PHARMACEUTICAL CO LTD [JP]) 21 April 2004 (2004-04-21) paragraph [0010] paragraph [0021] paragraph [0068] - paragraph [0071]	1-11
Y	WO 2005/023301 A (ABURATANI HIROYUKI [JP]; CHUGAI PHARMACEUTICAL CO LTD [JP]; PERSEUS PR) 17 March 2005 (2005-03-17) the whole document -/-	1-11

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

2 April 2007

Date of mailing of the international search report

13/04/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Irion, Andrea

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/039682

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	& EP 1 671 645 A (CHUGAI PHARMACEUTICAL CO LTD [JP]; PERSEUS PROTEOMICS INC [JP]; ABURAT) 21 June 2006 (2006-06-21) paragraph [0010] paragraph [0011] paragraph [0018] paragraph [0072] - paragraph [0075] paragraph [0059] -----	1-11
Y	WO 2004/099249 A (XENCOR [US]; LAZAR GREGORY ALAN [US]; CHIRINO ARTHUR J [US]; DANG WEI) 18 November 2004 (2004-11-18) paragraph [0024] - paragraph [0031] the whole document -----	1-11
P,Y	WO 2006/006693 A (CHUGAI PHARMACEUTICAL CO LTD [JP]; NAKANO KIYOTAKA [JP]; YOSHINO TAKES) 19 January 2006 (2006-01-19) the whole document -----	1-11
P,Y	& EP 1 674 111 A (CHUGAI PHARMACEUTICAL CO LTD [JP]) 28 June 2006 (2006-06-28) the whole document -----	1-11
P,Y	WO 2006/022407 A (CHUGAI PHARMACEUTICAL CO LTD [JP]; KINOSHITA YASUKO [JP]; SUGIMOTO MAS) 2 March 2006 (2006-03-02) the whole document -----	1-11
P,Y	WO 2006/046751 A (CHUGAI PHARMACEUTICAL CO LTD [JP]; NAKANO KIYOTAKA [JP]; SUGO IZUMI [J]) 4 May 2006 (2006-05-04) paragraph [0064] -----	1-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2006/039682

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 7 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2006/039682

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1411118	A1	21-04-2004	CA 2451493 A1 CN 1688692 A WO 03000883 A1 US 2004236080 A1	03-01-2003 26-10-2005 03-01-2003 25-11-2004
WO 2005023301	A	17-03-2005	EP 1671645 A1	21-06-2006
EP 1671645	A	21-06-2006	WO 2005023301 A1	17-03-2005
WO 2004099249	A	18-11-2004	AU 2004236160 A1 BR PI0410031 A CA 2524399 A1 EP 1620467 A2 KR 20050116400 A	18-11-2004 25-04-2006 18-11-2004 01-02-2006 12-12-2005
WO 2006006693	A	19-01-2006	AU 2005256113 A1 BR PI0506125 A CA 2544692 A1 CN 1842540 A EP 1674111 A1 MX PA06002890 A	30-03-2006 24-10-2006 19-01-2006 04-10-2006 28-06-2006 05-06-2006
EP 1674111	A	28-06-2006	AU 2005256113 A1 BR PI0506125 A CA 2544692 A1 CN 1842540 A WO 2006006693 A1 MX PA06002890 A	30-03-2006 24-10-2006 19-01-2006 04-10-2006 19-01-2006 05-06-2006
WO 2006022407	A	02-03-2006	NONE	
WO 2006046751	A	04-05-2006	NONE	